Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

Abstract Background Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. There is a lack...

Full description

Bibliographic Details
Main Authors: A. van Ommen-Nijhof, I. R. Konings, C. J. J. van Zeijl, C. A. Uyl-de Groot, V. van der Noort, A. Jager, G. S. Sonke, On behalf of the SONIA study steering committee
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Cancer
Subjects:
Advanced breast cancer
Metastatic breast cancer
Palbociclib
Ribociclib
Abemaciclib
CDK4/6 inhibitors
Online Access:http://link.springer.com/article/10.1186/s12885-018-4978-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4978-1

Similar Items